Takeda fails to gain FDA approval of diabetes drug alogliptin

04/25/2012 | MedCityNews.com

The FDA issued a complete response letter to Takeda Pharmaceutical for diabetes drug alogliptin as stand-alone treatment and in combination with Actos, another therapy by the drugmaker. Takeda, which licensed alogliptin from Furiex Pharmaceuticals, "will immediately request a meeting with the FDA to determine the appropriate next steps and [is] committed to addressing outstanding issues," said Thomas Harris, vice president of regulatory affairs at Takeda Global Research & Development Center.

View Full Article in:

MedCityNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR